Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $2.35B.
ENTERPRISE VALUE (EV)
$2.35B
BioCryst Pharmaceuticals, Inc.
Market Cap
$2.02B
Enterprise Value (EV)
$2.35B
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| BioCryst Pharmaceuticals, Inc. (BCRX) | $2.02B | $2.35B |
| UroGen Pharma Ltd. (URGN)vs › | $2.02B | $2.14B |
| Fortrea Holdings Inc. (FTRE)vs › | $2.01B | $2.96B |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.01B | $1.89B |
| Progyny, Inc. (PGNY)vs › | $2.03B | $1.90B |
| Vericel Corporation (VCEL)vs › | $2.05B | $2.02B |
| Viridian Therapeutics, Inc. (VRDN)vs › | $2.06B | $2.14B |
| Inspire Medical Systems, Inc. (INSP)vs › | $1.97B | $1.88B |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.07B | $2.03B |
| Alvotech (ALVO)vs › | $2.07B | $3.38B |
Market Cap
$2.02B
Total Debt
$427.23M
Cash
$89.74M
Enterprise Value
$2.35B
Why use EV instead of Market Cap?
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
